Financial highlights Business In 2023, we continued our progress towards leadership in medical dermatology driven by strong growth in the European Dermatology business. This performance was achieved by delivering against our key growth drivers and new launches, and led to the achievement of our 2023 guidance. Strong operational performance, driven by the excellent momentum of the medical dermatology business in Europe, meant that we maintained the positive trend experienced in 2022. The continued sales growth in dermatological products across different regions in Europe was mainly attributed to the commercial deployment of Klisyri® (tirbanibulin) and Wynzora® (calcipotriol/betamethasone) in new territories, along with the increase in sales of Ilumetri® (tildrakizumab) in various established countries. Based on the strong results in 2023, we made significant progress on our roadmap towards leadership in medical dermatology. Anto, living with psoriasis.